Argenta delivers preclinical candidate for Wellcome Trust funded, anti-aging project
Argenta, a service division of Galapagos NV, announced that it recently concluded contract research support to the University of Edinburgh for a Wellcome Trust funded Seeding Drug Discovery Initiative (SDDI) project resulting in the successful identification of a preclinical candidate.
The three-year project aimed at identifying selective inhibitors of the 11beta-HSD1 enzyme resulted in the identification of a lead candidate. The class of compounds, which will hopefully enter human clinical trials next year, is being investigated as a potential drug that could slow the natural decline in memory associated with aging. The preclinical candidate has been shown to improve cognitive and memory function in aging mice. The nomination of this preclinical candidate brings the total number of such candidates identified by Argenta in its 10 year history to over 35.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.